{"id":123,"date":"2009-05-18T13:52:26","date_gmt":"2009-05-18T18:52:26","guid":{"rendered":"http:\/\/blogviejo.sld.cu\/inorbib\/?page_id=123"},"modified":"2015-04-10T13:46:51","modified_gmt":"2015-04-10T13:46:51","slug":"oncoenlaces-guias-de-practica-clinica","status":"publish","type":"page","link":"https:\/\/blogs.sld.cu\/inorbib\/oncoenlaces-guias-de-practica-clinica\/","title":{"rendered":"OncoEnlaces- Gu\u00edas de Pr\u00e1ctica Cl\u00ednica"},"content":{"rendered":"<p style=\"text-align: left\"><a href=\"http:\/\/www.asco.org\/ASCOv2\/Practice+%26+Guidelines\/Guidelines\/Clinical+Practice+Guidelines\" target=\"_blank\">American Society of\u00a0 Clinical Oncology- Clinical practice guidelines<\/a><br \/>\n<a href=\"http:\/\/www.esmo.org\/Guidelines\" target=\"_blank\">European Society for Medical Oncology- Clinical practice guidelines<br \/>\n<\/a> <a href=\"http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp\" target=\"_blank\">NCCN- Clinical Practice Guidelines in Oncology<\/a><br \/>\n<a href=\"http:\/\/www.cancer.gov\/espanol\/recursos\/pdq\" target=\"_blank\"> National Cancer Institute- PDQ (Physician Data Query)<br \/>\n<\/a><br \/>\n<a href=\"http:\/\/www.esmo.org\/research\/esmo-clinical-recommendations.html#c741\" target=\"_blank\"><br \/>\n<\/a><br \/>\n<a href=\"http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp\" target=\"_blank\"><br \/>\n<\/a><br \/>\n<a href=\"http:\/\/www.guiasalud.es\/newCatalogo.asp\" target=\"_blank\"><br \/>\n<\/a><br \/>\n<a href=\"http:\/\/www.cma.ca\/index.cfm\/ci_id\/54344\/la_id\/1.htm?categoryCode=ONC\/MD&amp;categoryName=Medical%20oncology\" target=\"_blank\"><br \/>\n<\/a><br \/>\ntreatment with pembrolizumab in ipilimumab-refractory advanced melanoma:<\/p>\n","protected":false},"excerpt":{"rendered":"<p>American Society of\u00a0 Clinical Oncology- Clinical practice guidelines European Society for Medical Oncology- Clinical practice guidelines NCCN- Clinical Practice Guidelines in Oncology National Cancer Institute- PDQ (Physician Data Query) treatment with pembrolizumab in ipilimumab-refractory advanced melanoma:<\/p>\n","protected":false},"author":176,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"open","ping_status":"open","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/pages\/123"}],"collection":[{"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/users\/176"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/comments?post=123"}],"version-history":[{"count":2,"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/pages\/123\/revisions"}],"predecessor-version":[{"id":2551,"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/pages\/123\/revisions\/2551"}],"wp:attachment":[{"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/media?parent=123"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}